Thursday, 15 October 2026European Markets

COLRUYT Stock Bullish Momentum With A 15.57% Rise On Wednesday

Loading stream...

(VIANEWS) - The Market ended the session with COLRUYT (COLR.BR) rising 15.57% to €29.10 on Wednesday, following the last session's upward trend. BEL 20 jumped 0.28% to €3,770.88, following the last session's downward trend on what was a somewhat up trend trading session today.

About COLRUYT

Etn. Fr. Colruyt NV, together with its subsidiaries, engages in the retail, wholesale, food service, and other activities in Belgium, France, and internationally. It operates through three segments: Retail, Wholesale and Foodservice, and Other Activities. The company operates CNG and hydrogen filling stations; provides printing and document management solutions; and develops, constructs, operates, and finances wind energy projects. In addition, the company provides fresh products, dry food, and frozen and non-food products. It provides its products and services to wholesalers, commercial customers, and affiliated independent merchants, as well as, schools, care homes, the hospitality sector, etc. The company was founded in 1928 and is headquartered in Halle, Belgium.

Earnings Per Share

As for profitability, COLRUYT has a trailing twelve months EPS of €1.64.

PE Ratio

COLRUYT has a trailing twelve months price to earnings ratio of 17.74. Meaning, the purchaser of the share is investing €17.74 for every euro of annual earnings.

Volatility

COLRUYT's last week, last month's, and last quarter's current intraday variation average was a negative 0.08%, a negative 0.40%, and a positive 1.25%.

COLRUYT's highest amplitude of average volatility was 0.20% (last week), 1.07% (last month), and 1.25% (last quarter).

More news about COLRUYT (COLR.BR).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com